Literature DB >> 35913585

STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model.

Shuhei Kii1,2, Hidemitsu Kitamura3, Shinichi Hashimoto4, Kazuho Ikeo5, Nobuki Ichikawa2, Tadashi Yoshida2, Shigenori Homma2, Mishie Tanino6, Akinobu Taketomi2.   

Abstract

BACKGROUND: The development of inflammatory bowel diseases is thought to be multifactorial, but the exact steps in pathogenesis are poorly understood. In this study, we investigated involvement of the activation of STAT1 signal pathway in the pathogenesis of an acute colitis model.
METHODS: A dextran sulfate sodium-induced acute colitis model was established by using wild-type C57BL/6 mice and STAT1-deficient mice. Disease indicators such as body weight loss and clinical score, induction of cytokines, chemokines, and inflammatory cells were evaluated in the acute colitis model.
RESULTS: Disease state was significantly improved in the acute colitis model using STAT1-deficient mice compared with wild-type mice. The induction of Ly6c-highly expressing cells in colorectal tissues was attenuated in STAT1-deficient mice. IL-6, CCL2, and CCR2 gene expressions in Ly6c-highly expressing cells accumulated in the inflamed colon tissues and were significantly higher than in Ly6c-intermediate-expressing cells, whereas TNF-α and IFN-α/β gene expression was higher in Ly6c-intermediate-expressing cells. Blockade of CCR2-mediated signaling significantly reduced the disease state in the acute colitis model.
CONCLUSIONS: Two different types of Ly6c-expressing macrophages are induced in the inflamed tissues through the IFN-α/β-STAT1-mediated CCL2/CCR2 cascade and this is associated with the pathogenesis such as onset, exacerbation, and subsequent chronicity of acute colitis.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CCR2; Inflammatory bowel disease; Ly6c; Macrophages; Signal transducer and activator of transcription 1

Mesh:

Substances:

Year:  2022        PMID: 35913585     DOI: 10.1007/s00011-022-01620-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   6.986


  55 in total

Review 1.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

2.  A Weaning Reaction to Microbiota Is Required for Resistance to Immunopathologies in the Adult.

Authors:  Ziad Al Nabhani; Sophie Dulauroy; Rute Marques; Clara Cousu; Shahed Al Bounny; François Déjardin; Tim Sparwasser; Marion Bérard; Nadine Cerf-Bensussan; Gérard Eberl
Journal:  Immunity       Date:  2019-03-19       Impact factor: 31.745

Review 3.  Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships.

Authors:  Damian R Plichta; Daniel B Graham; Sathish Subramanian; Ramnik J Xavier
Journal:  Cell       Date:  2019-08-22       Impact factor: 41.582

Review 4.  Environmental triggers in IBD: a review of progress and evidence.

Authors:  Ashwin N Ananthakrishnan; Charles N Bernstein; Dimitrios Iliopoulos; Andrew Macpherson; Markus F Neurath; Raja A Raja Ali; Stephan R Vavricka; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

5.  Disease-specific alterations in the enteric virome in inflammatory bowel disease.

Authors:  Jason M Norman; Scott A Handley; Megan T Baldridge; Lindsay Droit; Catherine Y Liu; Brian C Keller; Amal Kambal; Cynthia L Monaco; Guoyan Zhao; Phillip Fleshner; Thaddeus S Stappenbeck; Dermot P B McGovern; Ali Keshavarzian; Ece A Mutlu; Jenny Sauk; Dirk Gevers; Ramnik J Xavier; David Wang; Miles Parkes; Herbert W Virgin
Journal:  Cell       Date:  2015-01-22       Impact factor: 41.582

Review 6.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

Authors:  Siew C Ng; Hai Yun Shi; Nima Hamidi; Fox E Underwood; Whitney Tang; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung; Gilaad G Kaplan
Journal:  Lancet       Date:  2017-10-16       Impact factor: 79.321

7.  Butyrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent Mechanism.

Authors:  José Luís Fachi; Jaqueline de Souza Felipe; Laís Passariello Pral; Bruna Karadi da Silva; Renan Oliveira Corrêa; Mirella Cristiny Pereira de Andrade; Denise Morais da Fonseca; Paulo José Basso; Niels Olsen Saraiva Câmara; Éricka Lorenna de Sales E Souza; Flaviano Dos Santos Martins; Suzana Eiko Sato Guima; Andrew Maltez Thomas; João Carlos Setubal; Yuli Thamires Magalhães; Fábio Luis Forti; Thamiris Candreva; Hosana Gomes Rodrigues; Marcelo Bispo de Jesus; Sílvio Roberto Consonni; Alessandro Dos Santos Farias; Patrick Varga-Weisz; Marco Aurélio Ramirez Vinolo
Journal:  Cell Rep       Date:  2019-04-16       Impact factor: 9.423

Review 8.  Microbial genes and pathways in inflammatory bowel disease.

Authors:  Melanie Schirmer; Ashley Garner; Hera Vlamakis; Ramnik J Xavier
Journal:  Nat Rev Microbiol       Date:  2019-08       Impact factor: 60.633

9.  Host genotype and early life microbiota alterations have additive effects on disease susceptibility.

Authors:  Timothy C Borbet; Martin J Blaser
Journal:  Mucosal Immunol       Date:  2019-03-11       Impact factor: 7.313

10.  Gut mucosal virome alterations in ulcerative colitis.

Authors:  Tao Zuo; Xiao-Juan Lu; Yu Zhang; Chun Pan Cheung; Siu Lam; Fen Zhang; Whitney Tang; Jessica Y L Ching; Risheng Zhao; Paul K S Chan; Joseph J Y Sung; Jun Yu; Francis K L Chan; Qian Cao; Jian-Qiu Sheng; Siew C Ng
Journal:  Gut       Date:  2019-03-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.